7/103 sources · 3 publishersUpdated Oct 15, 20:15 UTC
Goldman Sachs lifts Moderna price target to $137, keeps Neutral rating
Goldman Sachs raised its price target for Moderna (MRNA) from $120 to $137 while maintaining a Neutral rating. The upgrade is driven by upcoming Phase 3 melanoma data and early Phase 1 pancreatic cancer results. The firm also noted recent insider selling of about $49.2 million over the past three months.
Why it matters
The higher target may support the stock’s recent rally toward 52‑week highs, as investors weigh the potential upside from the pending oncology data. Insider sell activity of $49,184,366 could signal caution among company insiders, adding a counter‑balance to the bullish target.
Key facts
- 1Goldman Sachs raised its price target on Moderna to $137 from $120. tipranks.com
- 2The firm kept a Neutral rating on the shares. tipranks.com
- 3Phase 3 melanoma results expected at ESMO on October 24 are cited as a key catalyst. tipranks.com
- 4Insider selling totaled $49,184,366 over the past three months. gurufocus.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.